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Our study (Barnicot & Crawford 2018) was a non-randomised comparison of outcomes in 
routine clinical services implementing different treatment models for borderline personality 
disorder (BPD): mentalization-based therapy (MBT) and dialectical behaviour therapy 
(DBT). Our study’s contribution lies primarily in its novelty as currently the only head-to-
head comparison of these treatment models, and its potential to generate exploratory findings 
for further testing in a definitive randomised controlled trial. We thank Luyten and colleagues 
for their useful commentary. 
Pre-treatment differences  
Whilst pre-treatment dissociation and BPD severity were equivalent between treatment 
groups, DBT patients exhibited significantly greater emotional dysregulation and likelihood 
of PTSD, self-harming behaviour, and A&E admission in the 12 months before treatment 
(67% vs. 34%) (Barnicot & Crawford 2018, Table 1). Additionally, DBT patients exhibited 
clinically significantly, (although statistically non-significantly), higher rates of depression 
(43% vs. 25%), alcohol dependence (25% vs. 13%) and psychotic symptoms (46% vs. 35%). 
These may be chance differences, or viewed collectively, may raise questions about referral 
bias and participant self-selection, reinforcing the importance of randomised treatment 
allocation in future studies. 
 
Reporting of findings 
We agree that pre-registration and specification of primary outcomes is essential for 
randomised controlled trials. However, our study was not a clinical trial. We have fully 
reported and discussed all findings in our abstract, results and discussion.  
Change in self-harm and emotional dysregulation  
We based our conclusion that reductions in self-harm and emotional dysregulation were 
greater in DBT on our finding that, in both unadjusted and adjusted multi-level mixed-effects 
models, there was a significant treatment-by-time interaction favouring DBT for these 
outcomes. Two trials very recently published in this journal (July 2019 issue) used similar 
models to examine the rate of change in the outcome variables as their primary analysis 
(Freyer-Adam et al. 2019, Strauss et al. 2019), as did a largescale trial of MBT conducted by 
the treatment developer (Bateman et al. 2009). Further post-hoc analysis of our treatment-by-
time interaction effect shows a larger decrease in emotional dysregulation and self-harm per 
month in DBT patients. MBT patients showed an estimated 1.08 point decrease in emotional 
dysregulation per month (β = -1.08, 95% CI -1.74 to –0.43, p = 0.001) compared to a 2.49 
point estimated decrease per month in DBT patients (β = -2.49, 95% CI -3.15 to -1.83, 
p<0.001). MBT patients showed an estimated 0.95 times decrease in the rate of self-harm per 
month (IRR = 0.95, 95% CI 0.91 to 0.99, p =0.008) and DBT patients a 0.89 times estimated 
decrease per month (IRR = 0.89, 95% CI 0.86 to 0.92, p < 0.001). This fully justifies our 
conclusion that reductions in self-harm and emotional dysregulation were greater in DBT.  
Luyten and colleagues usefully highlight the lack of between-groups difference in emotional 
dysregulation and self-harm at the 12-month follow-up (Barnicot & Crawford 2018, Table 2), 
suggesting therefore that patients followed different trajectories towards the same endpoint. 
Unlike our mixed-effects models – which benefited from incorporating data from multiple 
timepoints and maximum-likelihood-based modelling, increasing statistical power and 
robusticity to loss to follow-up (Tango 2016) - our sample size for outcome comparison at 12 
months was restricted by using data from a single timepoint, and by loss to follow-up.  
Substantial overdispersion in self-harm incidents further reduced statistical power.  We agree 
that the 6-point difference in emotional dysregulation score at month 12 is neither statistically 
nor clinically significant – thus whilst the rate of improvement in emotional dysregulation 
was significantly faster amongst DBT patients, outcomes at the end of 12 months were 
similar. By contrast, there were large and clinically significant (but statistically non-
significant) differences in self-harm. The median number of self-harm incidents between 
months 10 and 12 was 2 in the DBT condition and 12.5 in the MBT condition (Barnicot & 
Crawford 2018, Table 2 – medians are presented due to the skewed data distribution (Field 
2013)). Thus, one possible interpretation is that the faster rate of improvement in self-harm in 
DBT was accompanied by a clinically significantly lower rate of self-harm by 12 months, 
which failed to reach statistical significance. A largescale adequately powered trial is 
required to determine whether there is a statistically significant difference in self-harm at 12 
months or any other timepoint.  
Reporting of findings from unadjusted and adjusted models 
We strongly refute the suggestion that we have shown allegiance bias by only presenting 
adjusted models where findings from unadjusted models disadvantaged DBT. Firstly, whilst 
we are not privy to all unconscious biases that dwell within us, Barnicot is a non-clinical 
academic unaffiliated with any particular therapeutic paradigm; Crawford is a trained MBT 
therapist and delivered MBT in one of the participating treatment centres. Thus, any bias 
might be expected to favour MBT, not DBT. Secondly, our choice of when to present 
adjusted models was based solely on an objective criterion: if an outcome was found to differ 
significantly between DBT and MBT patients in an unadjusted model, we presented findings 
from an adjusted model, in order to test whether the significant difference in the unadjusted 
model still held after adjusting for potential confounders. If an outcome was not found to 
differ significantly between DBT and MBT patients in unadjusted models, we did not run an 
adjusted model (Barnicot & Crawford 2018, Methods). This criterion applied both to findings 
favouring DBT and those favouring MBT.  
Treatment dropout  
Noting the markedly higher treatment dropout rate in DBT, and cautious of attributing any 
outcome differences to inherent effects of therapy modality that might instead be better 
explained by treatment dropout or factors linked to treatment dropout, we conservatively 
chose to adjust our models for any such factors. Therefore, as well as including baseline 
covariates differing significantly between DBT and MBT patients, we also included baseline 
covariates differing significantly between treatment completers and dropouts (Barnicot & 
Crawford 2018, Methods). Guidance on clinical trial analysis agrees that adjustment for 
treatment dropout can be useful in sensitivity analyses (European Medicines Agency 2015). 
However, we agree with Luyten and colleagues that caution is merited, as if a higher 
treatment dropout rate is a true property of DBT treatment and also associated with poorer 
outcomes, then adjusting for variance shared between DBT treatment and treatment dropout 
could obscure evidence of poorer outcomes in DBT (European Medicines Agency 2015). Our 
analyses were conducted on an intention-to-treat basis, including data collected from 
treatment dropouts following their treatment discontinuation. The requested replication of our 
analyses in the sample of treatment completers alone would restrict our sample size to n = 43 
at baseline and n = 40 at month 12, reducing the power of the study to detect any treatment 
differences. We do not believe this would be useful.  
Covariate-adjusted models in non-randomised studies 
Luyten and colleagues cite an important difficulty with adjustment for covariates whose 
effects overlap with treatment effects. This is particularly problematic in non-randomised 
studies, where it is impossible to determine whether pre-treatment differences between 
groups have arisen by chance or whether they constitute an inherent property of group 
membership, and thus by removing variance that is shared between the covariate and 
treatment exposure, adjustment for group differences may obscure or enhance treatment 
effects (Field 2013, Miller & Chapman 2001). However, this problem arises when covariates 
are related to treatment exposure, not to the dependent variable (Field 2013, pg. 484). Thus, 
the request that we exclude any covariates associated with our dependent variables would not 
solve the problem of shared variance with the treatment effect and would be contrary to 
clinical trial guidance (European Medicines Agency 2015). Despite this difficulty, UK 
National Institute for Health and Care Excellence (NICE) Decision Support Unit guidance 
stresses the importance of evaluating and adjusting for potentially confounding differences 
between treatment groups in non-randomised studies (Faria et al. 2015). A possible 
compromise may be found in the NICE recommendation that authors present sensitivity 
analyses to test whether their findings are robust to different analysis methods (Bell et al. 
2016).  
Conclusion 
Therefore, acknowledging the inherent difficulty of covariate adjustment given our non-
randomised study design, and yet also cognisant of the recommendation that consideration of 
confounders is important in such studies, we propose that our covariate-adjusted models be 
considered sensitivity analyses and their findings exploratory. Our unadjusted and adjusted 
analyses agree that the rate of change in emotional dysregulation and self-harm was superior 
amongst DBT patients. Thus, these findings seem robust to different analysis methods. Our 
unadjusted analyses also found statistically and clinically significantly higher rates of 
treatment dropout, A&E attendance and psychiatric hospitalisation amongst DBT patients, 
which were not apparent in adjusted models. This evidence of poorer outcomes amongst DBT 
patients merits further investigation. Whilst our adjusted analyses suggested these outcomes 
may have been influenced by differences between DBT and MBT patients in pre-treatment 
characteristics and treatment dropout, this does not detract from the importance of these 
negative outcomes, and the difficulties of adjusting for treatment dropout and interpreting 
covariate-adjusted analyses in non-randomised studies should be held in mind. Further 
evaluation using a randomised controlled trial design is essential in order to draw robust 
conclusions on these and other outcomes.  
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